8-K: Shattuck Labs Reports First Quarter 2024 Financial Results and Provides Clinical Pipeline Update

Shattuck Labs announced its first quarter 2024 financial results, highlighted by clinical trial advancements and a strategic collaboration with Ono Pharmaceutical.

Summary

• Shattuck Labs reported a net loss of $18.5 million for the first quarter of 2024, compared to a net loss of $20.7 million for the same period in 2023.
• Research and development expenses were $16.3 million, slightly down from $16.7 million in the first quarter of 2023.
• General and administrative expenses were $4.9 million, compared to $5.1 million in the first quarter of 2023.
• The company's cash and cash equivalents and investments totaled $114.6 million as of March 31, 2024, down from $135.5 million as of March 31, 2023.
• Shattuck expects its current cash reserves to fund operations into 2026.
• The company is advancing its lead program, SL-172154, in multiple Phase 1 clinical trials.
• A randomized, controlled Phase 1B dose-expansion cohort in frontline HR-MDS patients is expected to begin enrollment in the second quarter of 2024.
• Shattuck presented preclinical data at the AACR Annual Meeting, demonstrating the potential of TRIM7 inhibition to overcome resistance to immune checkpoint therapy.
• Shattuck entered into a collaboration agreement with Ono Pharmaceutical for the development of certain bifunctional fusion proteins for autoimmune and inflammatory diseases.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with clinical trial progress and a strategic partnership, but the ongoing losses and cash burn temper the enthusiasm. The company is making progress but still has risks.

Positives

• The net loss decreased to $18.5 million in Q1 2024 from $20.7 million in Q1 2023.
• The company's cash runway is projected to extend into 2026.
• Shattuck is progressing its clinical trials for SL-172154, with multiple data readouts expected in 2024.
• The collaboration with Ono Pharmaceutical expands the company's pipeline beyond oncology.
• The appointment of Clay Siegall and Kate Sasser to the board brings valuable industry experience.

Negatives

• Cash and cash equivalents decreased from $135.5 million in March 2023 to $114.6 million in March 2024.
• The company continues to operate at a loss, with a net loss of $18.5 million for the quarter.
• The company's cash runway guidance excludes potential additional capital, business development proceeds, and additional clinical development costs.

Risks

• The company's financial results are subject to various risks and uncertainties, including those related to clinical trial outcomes and regulatory approvals.
• The company's cash runway is dependent on current operational plans and may be impacted by unforeseen circumstances.
• There is a risk that clinical trial results may not be consistent with preclinical study results.
• The company's ability to obtain regulatory approvals and commercialize its products is subject to uncertainty.
• Global macroeconomic conditions and related volatility could impact the company's operations and financial performance.

Future Outlook

Shattuck believes its current cash and investments will be sufficient to fund operations into 2026, beyond the results from its Phase 1 clinical trials of SL-172154. This guidance excludes any additional capital, business development proceeds, and additional clinical development costs.

Management Comments

• We were pleased to see rapid enrollment to the expanded TP53m AML cohort in January.
• We also expect to see similarly rapid enrollment through the remainder of 2024 into the randomized and controlled expansion cohort in frontline HR-MDS patients.
• We remain excited about the profile of SL-172154 in frontline AML and HR-MDS and are looking forward to sharing additional response and initial survival data in June.
• In addition to our clinical momentum, we have continued to advance our pre-clinical pipeline to create additional opportunities for growth and value alongside SL-172154.

Industry Context

Shattuck's focus on bi-functional fusion proteins aligns with the growing interest in novel immunotherapies for cancer and autoimmune diseases. The collaboration with Ono Pharma highlights the industry trend of partnerships to expand therapeutic pipelines. The development of TRIM7 inhibitors to address resistance to checkpoint inhibitors is also a significant area of research in the immuno-oncology field.

Comparison to Industry Standards

• Shattuck's cash runway into 2026 is a positive sign, as many biotech companies face funding challenges.
• The company's R&D spending is consistent with other clinical-stage biotech companies, but the net loss indicates the need for further clinical success to attract investment.
• The collaboration with Ono Pharma is similar to other strategic partnerships in the biotech industry, where companies leverage each other's expertise and resources.
• The focus on novel targets like TRIM7 is in line with the industry's push for innovative approaches to overcome treatment resistance.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and the extended cash runway.
• Employees may be motivated by the company's advancements and strategic partnerships.
• Patients may benefit from the development of new therapies for cancer and autoimmune diseases.
• The collaboration with Ono Pharma may lead to new opportunities for both companies.

Next Steps

• Shattuck will present updated data from the Phase 1B expansion cohorts of SL-172154 in combination with azacitidine at the EHA 2024 Annual Meeting in June.
• The company expects to initiate enrollment in a randomized, controlled Phase 1B dose-expansion cohort in frontline HR-MDS patients in the second quarter of 2024.
• Shattuck anticipates completing enrollment in the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC in the second quarter of 2024.
• The company expects to share initial data from the Phase 1B clinical trial of SL-172154 in combination with PLD in PROC mid-year 2024.
• Shattuck will continue to advance its preclinical pipeline and explore additional opportunities for growth.

Key Dates

Keywords

Shattuck Labs, SL-172154, bi-functional fusion proteins, cancer, autoimmune disease, clinical trials, AML, HR-MDS, PROC, TRIM7, Ono Pharmaceutical, financial results